



## Review Article

## Coagulation and sepsis

Marcel Levi, MD<sup>a,b,\*</sup>, Tom van der Poll, MD<sup>c</sup><sup>a</sup> Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands<sup>b</sup> University College London Hospitals, London, United Kingdom<sup>c</sup> Center for of Experimental Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

## ARTICLE INFO

## Article history:

Received 2 October 2016

Received in revised form 5 November 2016

Accepted 9 November 2016

Available online 19 November 2016

## Keywords:

Sepsis

Coagulation

Inflammation

Coagulation inhibitors

Disseminated intravascular coagulation

## ABSTRACT

Severe sepsis is almost invariably associated with systemic activation of coagulation. There is ample evidence that demonstrates a wide-ranging cross-talk between hemostasis and inflammation, which is probably implicated in the pathogenesis of organ dysfunction in patients with sepsis. Inflammation not only leads to initiation and propagation of coagulation activity, but coagulation also markedly influences inflammation. Molecular mechanisms that play a role in inflammation-induced effects on coagulation have been recognized in much detail. Pro-inflammatory cells and cyto- and chemokines can activate the coagulation system and downregulate crucial physiological anticoagulant mechanisms. Initiation of coagulation activation and consequent thrombin generation is caused by expression of tissue factor on activated monocytes and endothelial cells and is ineffectually offset by tissue factor pathway inhibitor. At the same time, endothelial-associated anticoagulant pathways, in particular the protein C system, is impaired by pro-inflammatory cytokines. Also, fibrin removal is severely obstructed by inactivation of the endogenous fibrinolytic system, mainly as a result of upregulation of its principal inhibitor, plasminogen activator inhibitor type 1 (PAI-1). Increased fibrin generation and impaired break down lead to deposition of (micro)vascular clots, which may contribute to tissue ischemia and ensuing organ dysfunction. The foundation of the management of coagulation in sepsis is the explicit and thorough treatment of the underlying disorder by antibiotic treatment and source control measures. Adjunctive strategies focused at the impairment of coagulation, including anticoagulants and restoration of physiological anticoagulant mechanisms, may supposedly be indicated and have been found advantageous in experimental and initial clinical trials.

© 2016 Published by Elsevier Ltd.

## Contents

1. Sepsis and coagulation . . . . .	38
2. Frequency of clinically relevant coagulopathy in sepsis . . . . .	39
3. Pathways leading to coagulation abnormalities in sepsis . . . . .	39
4. Inflammation and the coagulopathy of sepsis . . . . .	39
5. Diagnosis of the coagulopathy in sepsis . . . . .	41
6. Supportive treatment of coagulation abnormalities in sepsis . . . . .	41
7. New pathways and targets in the management of DIC . . . . .	42
References . . . . .	42

## 1. Sepsis and coagulation

Sepsis is a very serious and potentially life-threatening complication of infection. Sepsis occurs when host-defense mediators released into

the circulation to combat the infection elicit systemic inflammatory responses throughout the body [1]. When the septic response leads to organ dysfunction, the term severe sepsis is used. Sepsis is a frequently occurring medical condition with an incidence of about 2.5 per 1000 in the Western world and an almost 10% annual rise over the last two decades [2]. About 20% of patients with sepsis die within the hospital and severe sepsis leads to mortality rates of approximately 40% [3]. Management of sepsis is aimed at adequate antibiotic therapy, source control,

\* Corresponding author at: Dept. Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.  
E-mail address: [m.m.levi@amc.uva.nl](mailto:m.m.levi@amc.uva.nl) (M. Levi).

and appropriate supportive care and organ function replacement, if needed.

Sepsis is almost invariably associated with coagulation abnormalities. These deviations range from delicate activation of coagulation that can only be identified by highly sensitive assays for coagulation factor activation to somewhat more severe hemostatic activation that may be noticeable by a subtle fall in platelet count and sub-clinical elongation of global clotting assays to fulminant disseminated intravascular coagulation (DIC), manifested by widespread microvascular thrombosis in small and mid-size vessels and simultaneous profuse hemorrhage from various sites [4,5]. Patients with sepsis and extensive forms of DIC may develop overt thrombo-embolic complications or clinically less apparent microvascular clot formation that may contribute to multiple organ failure [5,6]. In other cases, severe hemorrhage may be the dominant presentation [7], and frequently sepsis and DIC leads to simultaneous thrombosis and bleeding. Hemorrhage is due to consumption and subsequent depletion of coagulation factors and platelets, caused by ongoing activation of the hemostatic system [8]. In its most extreme manifestation this combination may present as the Waterhouse-Friderichsen syndrome, typically observed during fulminant meningococcal septicemia, although many other microorganisms may cause this clinical situation as well [9].

## 2. Frequency of clinically relevant coagulopathy in sepsis

Clinically relevant hemostatic changes may occur in 50 to 70% of septic patients, and approximately 35% of patients will meet the criteria for DIC [1,10]. The vast majority of patients with sepsis will develop thrombocytopenia (platelet count  $< 150 \times 10^9/l$ ) [11,12]. Commonly, platelet count drops in the first four days following admission to the hospital [13]. The severity of sepsis correlates strongly with the decrease in platelet count [14]. Crucial factors that cause thrombocytopenia in sepsis are decreased platelet production, enhanced consumption, obliteration, or sequestration in the spleen. Impaired production of megakaryocytes in the bone marrow may seem incongruous with the high levels of platelet production-stimulating pro-inflammatory mediators, such as tumor necrosis factor (TNF)- $\alpha$  and interleukin (IL)-6, and elevated levels of thrombopoietin in patients with sepsis, which theoretically should stimulate megakaryopoiesis [15]. However, in a large number of patients with sepsis substantial hemophagocytosis occurs, consisting of active phagocytosis of platelet precursors and other hematopoietic cells by mononuclear cells, presumably caused by elevated concentrations of macrophage colony stimulating factor (M-CSF) in sepsis [16]. Platelet consumption is presumably also important in sepsis, due to platelet activation secondary to continuous formation of thrombin. Platelet activation, consumption, and destruction takes place at the endothelial surface as a result of the widespread endothelial cell-platelet interaction in sepsis, although the extent may differ between various vascular beds of different organs [17]. Prolonged global coagulation assays (such as the prothrombin time (PT) or the activated partial thromboplastin time (aPTT)) is detectable in 15–30% of septic patients [18]. Other coagulation assay changes include high fibrin degradation products (in  $>95\%$  of patients with sepsis) [19,20] and low levels of physiological anticoagulants, such as antithrombin and protein C (90% of sepsis patients) [20,21].

## 3. Pathways leading to coagulation abnormalities in sepsis

In the last three decades the pathways involved in the coagulopathy of sepsis have for an important part been elucidated [4]. It is clear that various mechanisms in the coagulation system act simultaneously towards a prohemostatic state. Apparently the most important factors that mediate this derangement of the coagulation system during sepsis are cytokines. Ample evidence indicates an extensive cross-talk between inflammation and coagulation, where besides inflammation-induced coagulation activation but coagulation also markedly influences

inflammatory activity (Fig. 1) [22]. Of note, systemic activation of coagulation and inflammation in sepsis may manifest with organ-specific presentations that are relevant for the specific organ failure resulting from severe sepsis [23].


The most important initiator of thrombin formation in sepsis is tissue factor. Studies of experimental or human endotoxemia or cytokinemia have demonstrated a central role of the tissue factor/factor VIIa system in the initiation of thrombin generation [24]. Abrogation of the tissue factor/factor VII(a) pathway by specific interventions aimed at tissue factor or factor VIIa activity resulted in a complete abrogation of thrombin generation in experimental settings [25,26]. Also, in severe Gram negative sepsis, ex vivo tissue factor expression on monocytes of patients was demonstrated [27]. Experimental low dose endotoxemia in healthy humans resulted in a 125-fold increase in tissue factor mRNA levels in blood monocytes [28]. An alternative source of tissue factor may be its localization on other blood cells [29], although it is not likely that these cells themselves produce tissue factor in substantial quantities [30]. Based on the assessment of transfer of tissue factor from mononuclear cells to activated platelets in an ex vivo perfusion setting, it was postulated that this 'blood borne' tissue factor is shuttled between cells through microparticles [31].

Platelets have a central role in the development of coagulation abnormalities in sepsis. Platelets can be triggered directly by pro-inflammatory mediators, such as platelet activating factor [32]. Generated thrombin will further activate platelets. Activation of platelets may also stimulate fibrin formation by alternative mechanism. The expression of P-selectin on the platelet membrane not only mediates the adherence of platelets to leukocytes and endothelial cells but also enhances the expression of tissue factor on monocytes [33]. The underlying molecular pathway relies on nuclear factor kappa-B (NF $\kappa$ B) expression, induced by binding of activated platelets to neutrophils and monocytes. P-selectin can be shed from the surface of platelets membrane and soluble P-selectin levels are indeed increased during systemic inflammation [33].

In normal circumstances activation of coagulation is controlled by three important physiological anticoagulant pathways: the antithrombin system, the activated protein C system and tissue factor pathway inhibitor (TFPI). In sepsis all three pathways are importantly deranged [34]. Due to a combination of impaired synthesis, ongoing consumption and proteolytic degradation (e.g. by neutrophilic elastase) levels of all three coagulation inhibitors are low. Also, significant downregulation of thrombomodulin and endothelial protein C receptor (EPCR) in inflammatory conditions will cause impaired conversion of protein C to activated protein C. In addition, at the time of the greatest activation of coagulation in sepsis, endogenous fibrinolysis is largely turned off. After the acute release of plasminogen activators (i.e. tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA)) from storage sites in vascular endothelial cells during inflammatory conditions, the increase in plasminogen activation and subsequent plasmin generation, is annihilated by a sustained increase in plasminogen activator inhibitor, type 1 (PAI-1) [35]. Of interest, studies have shown that a functional mutation in the PAI-1 gene, the 4G/5G polymorphism, not only affected the plasma levels of PAI-1, but was also linked to clinical outcome of Gram negative sepsis. Patients with the 4G/4G genotype had significantly higher PAI-1 concentrations and an increased mortality [36]. Other studies showed that the PAI-1 polymorphism increased the risk of developing septic shock from meningococcal infection [37].

## 4. Inflammation and the coagulopathy of sepsis

Like virtually all systemic inflammatory effects of infection, the derangement of the hemostatic system in sepsis is orchestrated by several cytokines. Most pro-inflammatory cytokines have been demonstrated to initiate coagulation activation in vitro. In sepsis high levels of cytokines can be found in the circulation of affected patients and



**Fig. 1.** Interaction between inflammation and coagulation in sepsis. Expression of tissue factor in mononuclear cells and subsequent exposure to blood results in thrombin generation followed by fibrinogen to fibrin conversion. Simultaneously, platelet vessel wall interaction and activation of platelets contribute to (micro)vascular clot formation. Platelet-derived P-selectin further enhances tissue factor expression. Binding of tissue factor, thrombin, and other activated coagulation proteases to specific protease activated receptors (PAR's) and binding of fibrin to Toll-like receptor 4 on inflammatory cells affects inflammation through the consequent release of pro-inflammatory cytokines and chemokines, which further modulate coagulation and fibrinolysis.

investigational infection or experimental endotoxemia results in the transient increase in plasma levels of these cytokines [24]. The cytokine tumor necrosis factor (TNF) is the first mediator that becomes detectable, followed by an increase in serum levels of several interleukins (IL), of which IL-6 and IL-1 are prominent. Simultaneously, anti-inflammatory cytokines (such as IL-10) may have an inhibitory role in the activation of coagulation.

As TNF is the principal cytokine to become detectable in the circulation upon bacteremia and this cytokine has potent procoagulant effects, it was initially believed that hemostatic activation in sepsis was mediated by TNF. However, in several trials using different strategies to block TNF activity it was shown that the endotoxin-induced induction of TNF could be completely abrogated whereas activation of coagulation was not affected, albeit that the effects on coagulation inhibitors and fibrinolysis seemed to be regulated by TNF [24]. Also, in animals infused with a lethal dose of *E. coli*, an anti-TNF antibody had little or no effect on fibrinogen consumption or clinical outcome [38]. In line with this, clinical trials with an anti-TNF monoclonal antibody in septic patients did not show any advantage [39]. Interestingly, it was demonstrated in subsequent studies that strategies that blocked IL-6 caused a complete inhibition of endotoxin-induced activation of coagulation [40]. Also, studies in cancer patients with recombinant IL-6 showed that following the infusion of this cytokine marked thrombin generation occurred [41]. Hence, these results suggest that IL-6 rather than TNF is important as a mediator for cytokine-induced coagulation activation. Whereas IL-1 is a potent agonist of tissue factor expression in vitro, its role has not been fully elucidated in vivo. Administration of an IL-1 receptor antagonist partly blocked the procoagulant response in experimental sepsis models and inhibited thrombin generation in patients [42]. However, most of the alterations in coagulation occur well before

IL-1 becomes detectable in the circulation, leaving a potential role of IL-1 in the coagulopathy of sepsis an unsettled issue.

Coagulation factors and anticoagulant proteins do not only play a role in hemostatic activation, but also interact with specific cell receptors leading to activation of signaling pathways (Fig. 1). Specifically, protease interactions that modulate inflammatory processes may be important in sepsis. The most significant pathways by which coagulation factors regulate inflammation is by binding to protease activated receptors (PARs). PARs are transmembrane G-protein coupled receptors and 4 different types (PAR 1–4) have been recognized [43]. A typical property of PARs is that they serve as their own ligand. Proteolytic cleavage by an activated coagulation factor leads to exposure of a neoamino terminus, that is capable of activating the same receptor (and presumably adjacent receptors), leading to transmembrane signaling. PAR's 1, 3, and 4 are receptors that are activated by thrombin while PAR-2 is triggered by the tissue factor-factor VIIa complex, factor Xa, and trypsin. PAR-1 is also a receptor for the tissue factor-factor VIIa complex and factor Xa.

It has become apparent that there is significant cross-talk between coagulation inhibitors and inflammatory mediators as well. Antithrombin can serve as a regulator of inflammation, e.g. by direct binding to inflammatory cells and thereby reducing cytokine and chemokine receptor expression [44]. Also, there is ample evidence that the protein C system importantly regulates inflammatory activity [45]. Activated protein C has been demonstrated to attenuate endotoxin-induced production of TNF- $\alpha$ , IL-1 $\beta$ , IL-6 and IL-8 by monocytes/macrophages [46]. In addition, activated protein C blocks cytokine release and leukocyte activation in experimental bacteremia in vivo [47]. Inhibition of the protein C pathway by a monoclonal antibody aggravates the inflammatory response, as shown by enhanced levels of pro-inflammatory

cytokines and increased leukocyte activation and tissue damage [48]. Mice with a heterozygous protein C deficiency due to targeted disruption of the protein C gene have not only a stronger hemostatic response to experimental endotoxemia but also show marked differences in inflammatory responses (e.g. higher levels of circulating pro-inflammatory cytokines) [49].

## 5. Diagnosis of the coagulopathy in sepsis

There are several other causes for coagulation changes in septic patients. A low platelet count is almost invariably present in patients with severe sepsis, but thrombocytopenia may also be due to other (potentially concurrently present) conditions, such as immune thrombocytopenia, heparin-induced thrombocytopenia, thrombotic microangiopathies, or medication-induced bone marrow depression [50]. It is crucial to adequately diagnose these differential causes of thrombocytopenia, as they may necessitate specific management strategies [17]. Laboratory assays can be useful in differentiating the coagulopathy in sepsis from various other hemostatic conditions, such as vitamin K deficit or liver insufficiency. As these disorders may be present at the same time with sepsis-associated coagulopathy, this differentiation is not always easy [51,52].

According to the contemporary thinking about sepsis-associated coagulopathy the assessment of soluble fibrin in plasma appears to be important [53]. Generally, the sensitivity of assays for soluble fibrin for sepsis-associated coagulopathy is better than the specificity. Some clinical investigations have shown that at certain concentrations of soluble fibrin sepsis-associated coagulopathy is highly probable [19]. Most of the clinical trials show a sensitivity of 90–100% but simultaneously a rather low specificity [54]. Fibrin degradation products (FDP's) may be assayed by specific ELISA's or by latex agglutination assays, enabling quick and bed-side determination in urgent cases. None of the available tests for fibrin degradation products distinguishes degradation products of cross-linked fibrin or fibrinogen degradation, which may cause falsely abnormal results [55]. The specificity of high levels of fibrin split products is therefore modest and a series of other clinical situations, such as trauma, recent surgery, inflammation or venous thrombo-embolism, may cause elevated FDP's. More modern tests are specifically targeted at the determination of neo-antigens on degraded cross-linked fibrin. Typically these assays react with an epitope related to plasmin-degraded cross-linked  $\gamma$ -chain, resulting in fragment D-dimer. These tests better distinguish degradation of cross-linked fibrin from fibrinogen or fibrinogen degradation products [56].

Ongoing coagulation activation results in depletion of coagulation factors in septic patients. Also, reduced synthesis, e.g. caused by impaired liver function or vitamin K deficiency, and loss of coagulation factors, due to massive bleeding, may be important. Measurement of fibrinogen levels has been widely promoted as a helpful tool for the diagnosis of coagulation abnormalities in sepsis but in fact this is not very helpful in most cases [8,57]. Fibrinogen acts as an acute-phase reactant and despite considerable turnover plasma concentrations can be well within the normal range. In a consecutive series of patients the sensitivity of a low fibrinogen level for the diagnosis of DIC was <30% and hypofibrinogenemia was established in extreme cases of Gram negative septicemia only. Sequential assessment of fibrinogen might be more helpful and yield diagnostic insight.

Thrombelastography is increasingly employed in critically ill patients with a hypercoagulable state, including those with DIC [58,59]. Procoagulant as well as anticoagulant states in DIC as indicated with thrombelastography was demonstrated to have a good correlation with clinically important organ dysfunction and survival although its advantage over usual coagulation assays has not yet been confirmed [60–62]. In a systematic review of 2 randomized controlled trials and 16 observational studies in patients with sepsis it was demonstrated that thrombelastography was helpful in correctly identifying the endogenous fibrinolytic state [63]. The authors also found a correlation

between hypocoagulability in sepsis and increased mortality. The accurate use of thrombelastography for the diagnosis of DIC has not been rigorously evaluated although supporters believe that the assay may be helpful for appraising the state of coagulation in patients with critical illness [64,65].

Based on retrospective analyses of databases from critically ill patients composite scores for the diagnosis of sepsis-associated coagulopathy have been devised by the International Society on Thrombosis and Hemostasis (ISTH) [66]. The system is based on readily available laboratory tests, i.e. platelet count, prothrombin time, D-dimer, and fibrinogen levels. A diagnosis of DIC is compatible with a score of 5 or more points. The prothrombin time expressed in seconds in the scoring system may be replaced by the INR, making consistency between centres and standardization easier [67]. Validation analyses have shown a high diagnostic accuracy of the scoring system [68,69]. The intensity of the coagulopathy as judged by this composite score is strongly associated with survival rates in critically ill patients [70]. Combining predictive intensive care measurement systems such as Acute Physiology and Chronic Health Evaluation (APACHE-II) with the DIC score seems to be a potent method to predict the prognosis in septic patients. Similar composite scores have been designed and studied in Japan [71]. The most relevant discrepancies between the ISTH and Japanese scores are a higher sensitivity and a higher proportion of patients with haemato-oncological diseases that are diagnosed with DIC by the Japanese systems [72,73].

## 6. Supportive treatment of coagulation abnormalities in sepsis

The foundation of the treatment of septic coagulopathy is adequate management of the sepsis, e.g. by appropriate antibiotics and source control. However, in many situations adjunctive supportive treatment, aimed at replacement of organ function, is necessary. Likewise, coagulation may need supportive measures as the coagulopathy may proceed even after adequate sepsis treatment has been initiated. Some studies show that adjunctive interventions aimed at the derangement of coagulation may positively influence morbidity and mortality. The increase in the understanding of the various pathways that are important in coagulopathy of sepsis has indeed been helpful in the development of such adjunctive management strategies.

Low levels of platelets and coagulation factors may increase the risk of bleeding. However, plasma or platelet substitution therapy should not be instituted on the basis of laboratory results alone; it is indicated only in patients with active bleeding and in those requiring an invasive procedure or otherwise at risk for bleeding complications [74]. The presumed efficacy of treatment with plasma, fibrinogen, cryoprecipitate, or platelets is not based on randomized controlled trials but appears to be rational therapy in bleeding patients or in patients at risk for bleeding with a significant depletion of these hemostatic factors [34]. It may be required to use large volumes of plasma to restore normal concentrations of coagulation factors. Coagulation factor concentrates, such as prothrombin complex concentrate, may overcome this impediment, but these agents may lack important factors (e.g. factor V). Moreover, in older literature caution is advocated with the use of prothrombin complex concentrates in systemic coagulation activation, as it may aggravate the coagulopathy due to small traces of activated factors in the concentrate. It is, however, less likely that this is still the case for the concentrates that are currently in use. Specific deficiencies in coagulation factors, such as fibrinogen, may be corrected by administration of purified coagulation factor concentrates [34].

Experimental studies have shown that heparin can at least partly inhibit the activation of coagulation in sepsis [75]. Uncontrolled case series in patients with sepsis and DIC have claimed to be successful. However, an advantageous effect of heparin on clinically important outcome events in patients with DIC has never been clearly demonstrated in controlled clinical trials [76], although there is cumulating evidence that heparin might be beneficial [77,78]. In addition, there are several



studies showing that critically ill patients with sepsis need adequate prophylaxis for venous thromboembolism, usually with (low molecular weight) heparin [79,80]. Therapeutic doses of heparin are indicated in patients with clinically overt thromboembolism or extensive fibrin deposition, like purpura fulminans or acral ischemia. Patients with sepsis may benefit from prophylaxis to prevent venous thromboembolism, which may not be achieved with standard low-dose subcutaneous heparin [81].

Restoration of the levels of physiological anticoagulants in sepsis may be a rational approach [82]. Based on successful preclinical studies, the use of antithrombin concentrates has been examined mainly in randomized controlled trials in patients with severe sepsis. All trials have shown some beneficial effect in terms of improvement of laboratory parameters, shortening of the duration of the coagulopathy, or even improvement in organ function. In several small clinical trials, use of very high doses of antithrombin concentrate showed even a modest reduction in mortality, however, without being statistically significant. A large-scale, multicentre, randomized controlled trial also showed no significant reduction in mortality of patients with sepsis [83]. Interestingly, post-hoc subgroup analyses of this study indicated some benefit in patients who did not receive concomitant heparin and in those with the most severe coagulopathy [84]. Recent propensity-adjusted retrospective data from Japan demonstrated a significant benefit of antithrombin-treated patients with severe infection and sepsis [85,86]. However these observations still need prospective validation.

Adjunctive therapy with activated protein C (APC) has also been widely studied. A phase III trial of APC concentrate in patients with sepsis was prematurely stopped because of efficacy in reducing mortality in these patients [20]. All cause mortality at 28 days after inclusion was 24.7% in the APC group versus 30.8% in the control group (a 19.4% relative risk reduction). And there was also an improvement of coagulation abnormalities and reduced organ failure in APC-treated patients. Of note, patients with the most severe coagulopathy benefited most from this treatment [70]. However, series of negative trials in specific populations of patients with severe sepsis led to scepticism regarding the use of APC in sepsis and meta-analyses of published literature concluded that the basis for treatment with APC, even in patients with a high disease severity, was not very strong or even insufficient [87]. On top of that, there was uncertainty regarding the bleeding risk of APC in patients with severe sepsis. The last large placebo-controlled trial in patients with severe sepsis and septic shock was prematurely stopped due to the lack of any significant benefit of APC [88]. Subsequently, the manufacturer of APC has decided to withdraw the product from the market, which has resulted in a revision of current guidelines for treatment of DIC [89].

The most promising intervention at this moment is recombinant soluble thrombomodulin. Several preclinical studies in experimental sepsis models have shown that soluble thrombomodulin is capable of improving the derangement of coagulation and may restore organ dysfunction [90]. In phase I-II clinical studies the pharmacokinetic profile of recombinant soluble thrombomodulin was determined [91]. In a subsequent phase III randomized double-blind clinical trial in patients with DIC, administration of the soluble thrombomodulin had a significantly better effect on bleeding manifestations and coagulation parameters than heparin, but the mortality rate at 28 days was similar in the two study groups [92]. When limiting these results to patients with severe infection and sepsis, DIC resolution rates were 67.5% in thrombomodulin-treated patients and 55.6% in the control group, and 28-day mortality rates were 21.4% and 31.6%, respectively. Subsequently, soluble thrombomodulin was evaluated in a phase II/III clinical study in 750 patients with sepsis and disseminated intravascular coagulation [93]. Twenty-eight-day mortality was 17.8% in the thrombomodulin group and 21.6% in the placebo group. Markers of coagulation activation were lower in the thrombomodulin group than in the placebo group. There were no differences between groups in bleeding or thrombotic events. The promising results with recombinant soluble thrombomodulin are

supported by retrospective data in large series of Japanese patients and are currently being evaluated in a large international multicentre trial [94,95].

## 7. New pathways and targets in the management of DIC

In view of the overwhelming evidence for the central role of impaired natural anticoagulant pathways in the pathogenesis of DIC, much attention has been focused on the restoration of physiological anticoagulation as (adjunctive) treatment of DIC [4]. However, despite these interventions (such as recombinant human activated protein C or antithrombin concentrate) have shown efficacy in reversing the coagulopathy, they have not resulted in an improvement on clinically relevant outcomes, such as survival or improvement of organ dysfunction [96]. One of the factors responsible for this may be that all these anticoagulants are clearly limited by the potential risk of major hemorrhage in critically ill patients. Therefore, it has been hypothesized that molecules that have less anticoagulant properties but have retained their anti-inflammatory effects may be promising new agents for the management of DIC. For example, non-anticoagulant heparin inhibits the expression and function of adhesion molecules, such as P-selection and L-selectin. Moreover, this compound directly affects pro-inflammatory mediators, such as nuclear factor (NF)- $\kappa$ B and cytokines, and attenuates endothelial cell dysfunction through the nitric oxide system. Non-anticoagulant heparin has a strong affinity for extracellular histones that result from cellular destruction during severe inflammation and that are robustly associated with endothelial dysfunction, organ failure and death during sepsis [97]. Binding of this non-anticoagulant heparin to histones strongly inhibited cytotoxic activity in vitro and translated to impaired inflammation and improved survival in animal models of systemic infection and inflammation. Similarly, recent experiments indicate a beneficial effect of activated protein C variants that have lost their anticoagulant properties [98].

Another interesting new target may be the glycocalyx covering the endothelial surface of the vascular bed [99]. The endothelium of the capillary bed is the most important interface in which the interaction between inflammation and coagulation takes place. All physiologic anticoagulant systems and various adhesion molecules that may modulate both inflammation and coagulation are connected to the endothelium. In sepsis, endothelial glycosaminoglycans present in the glycocalyx are downregulated by proinflammatory cytokines, thereby impairing the functions of antithrombin (AT), tissue factor pathway inhibitor (TFPI), leukocyte adhesion, and leukocyte transmigration. Because the glycocalyx also plays a role in other endothelial functions, including maintenance of the vascular barrier function, nitric oxide-mediated vasodilation, and antioxidant activity, all these processes can be impaired in DIC. Moreover, specific disruption of the glycocalyx results in thrombin generation and platelet adhesion within a few minutes. Novel interventions aimed at restoration of the glycocalyx may potentially maintain adequate physiological anticoagulation to balance activated coagulation in DIC [100].

## References

- [1] A.P. Wheeler, G.R. Bernard, Treating patients with severe sepsis, *N. Engl. J. Med.* 340 (3) (1999) 207–214.
- [2] G.S. Martin, D.M. Mannino, S. Eaton, M. Moss, The epidemiology of sepsis in the United States from 1979 through 2000, *N. Engl. J. Med.* 348 (16) (2003) 1546–1554.
- [3] D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, M.R. Pinsky, Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care, *Crit. Care Med.* 29 (7) (2001) 1303–1310.
- [4] S. Gando, M. Levi, C.H. Toh, Disseminated intravascular coagulation, *Nat. Rev. Dis. Prim.* 2 (2016) 16037.
- [5] M. Levi, The coagulant response in sepsis, *Clin. Chest Med.* 29 (4) (2008) 627–642 (viii).
- [6] M. Levi, H. ten Cate, Disseminated intravascular coagulation, *N. Engl. J. Med.* 341 (8) (1999) 586–592.
- [7] D.L. Miller, K. Welty-Wolf, M.S. Carraway, M. Ezban, A. Ghio, H. Suliman, et al., Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine

- release after intratracheal lipopolysaccharide, *Am. J. Respir. Cell Mol. Biol.* 26 (6) (2002) 650–658.
- [8] M. Levi, H. ten Cate, T. van der Poll, Disseminated intravascular coagulation: state of the art, *Thromb. Haemost.* 82 (1999) 695–705.
- [9] O.D. Ratnoff, W.G. Nebbehay, Multiple coagulative defects in a patient with the Waterhouse-Friderichsen syndrome, *Ann. Intern. Med.* 56 (1962) 627.
- [10] M. Levi, E. de Jonge, T. van der Poll, Sepsis and disseminated intravascular coagulation, *J. Thromb. Thrombolysis* 16 (1–2) (2003) 43–47.
- [11] S. Vanderschueren, A. De Weerd, M. Malbrain, D. Vankersschaever, E. Frans, A. Wilmer, et al., Thrombocytopenia and prognosis in intensive care, *Crit. Care Med.* 28 (6) (2000) 1871–1876.
- [12] R. Strauss, M. Wehler, K. Mehler, D. Kreutzer, C. Koebnick, E.G. Hahn, Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome, *Crit. Care Med.* 30 (8) (2002) 1765–1771.
- [13] S. Akca, P. Haji Michael, A. de Medonca, P.M. Suter, M. Levi, J.L. Vincent, The time course of platelet counts in critically ill patients, *Crit. Care Med.* 30 (2002) 753–756.
- [14] A.C. Mavrommatis, T. Theodoridis, A. Orfanidou, C. Roussos, V. Christopoulou-Kokkinou, S. Zakyntinos, Coagulation system and platelets are fully activated in uncomplicated sepsis, *Crit. Care Med.* 28 (2) (2000) 451–457.
- [15] C.C. Folman, G.E. Linthorst, J. van Mourik, G. van Willigen, E. de Jonge, M. Levi, et al., Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis? *Thromb. Haemost.* 83 (6) (2000) 923–930.
- [16] B. Francois, F. Trimoreau, P. Vignon, P. Fixe, V. Praloran, H. Gastinne, Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor, *Am. J. Med.* 103 (2) (1997) 114–120.
- [17] T.E. Warkentin, W.C. Aird, J.H. Rand, Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome, *Hematology Am. Soc. Hematol. Educ. Program* (2003) 497–519.
- [18] J.B. MacLeod, M. Lynn, M.G. McKenney, S.M. Cohn, M. Murtha, Early coagulopathy predicts mortality in trauma, *J. Trauma* 55 (1) (2003) 39–44.
- [19] A.F. Shorr, S.J. Thomas, S.A. Alkins, T.M. Fitzpatrick, G.S. Ling, D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients, *Chest* 121 (4) (2002) 1262–1268.
- [20] G.R. Bernard, J.L. Vincent, P.F. Laterre, S.P. LaRosa, J.F. Dhainaut, A. Lopez-Rodriguez, et al., Efficacy and safety of recombinant human activated protein C for severe sepsis, *N. Engl. J. Med.* 344 (10) (Mar. 8, 2001) 699–709.
- [21] S. Gando, S. Nanzaki, S. Sasaki, O. Kemmotsu, Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation, *Thromb. Haemost.* 79 (6) (1998) 1111–1115.
- [22] M. Levi, T. van der Poll, H.R. Buller, The bidirectional relationship between coagulation and inflammation, *Circulation* 109 (22) (2004) 2698–2704.
- [23] W.C. Aird, Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis, *Crit. Care Med.* 29 (Suppl. 7) (2001) S28–S34.
- [24] M. Levi, T. van der Poll, Inflammation and coagulation, *Crit. Care Med.* 38 (Suppl. 2) (2010) S26–S34.
- [25] F.B. Taylor Jr., A. Chang, W. Ruf, J.H. Morrissey, L. Hinshaw, R. Catlett, et al., Lethal *E. coli* septic shock is prevented by blocking tissue factor with monoclonal antibody, *Circ. Shock* 33 (3) (1991) 127–134.
- [26] M. Levi, H. ten Cate, K.A. Bauer, T. van der Poll, T.S. Edgington, H.R. Buller, et al., Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees, *J. Clin. Investig.* 93 (1) (1994) 114–120.
- [27] B. Osterud, T. Flaegstad, Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis, *Thromb. Haemost.* 49 (1) (1983) 5–7.
- [28] R.F. Franco, E. de Jonge, P.E. Dekkers, J.J. Timmerman, C.A. Spek, et al., The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation, *Blood* 96 (2) (2000) 554–559.
- [29] P.L. Giesen, U. Rauch, B. Bohrmann, D. Kling, M. Roque, J.T. Fallon, et al., Blood-borne tissue factor: another view of thrombosis, *Proc. Natl. Acad. Sci. U. S. A.* 96 (5) (1999) 2311–2315.
- [30] B. Osterud, L.V. Rao, J.O. Olsen, Induction of tissue factor expression in whole blood - lack of evidence for the presence of tissue factor expression on granulocytes, *Thromb. Haemost.* 83 (2000) 861–867.
- [31] U. Rauch, D. Bolderman, B. Bohrmann, J.J. Badimon, J. Himber, M.A. Riederer, et al., Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor, *Blood* 96 (1) (2000) 170–175.
- [32] G.A. Zimmerman, T.M. McIntyre, S.M. Prescott, D.M. Stafforini, The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis, *Crit. Care Med.* 30 (Suppl. 5) (2002) S294–S301.
- [33] R.J. Shebuski, K.S. Kilgore, Role of inflammatory mediators in thrombogenesis, *J. Pharmacol. Exp. Ther.* 300 (3) (2002) 729–735.
- [34] M. Levi, T. Poll, Coagulation in patients with severe sepsis, *Semin. Thromb. Hemost.* 41 (1) (2015) 9–15.
- [35] B.J. Biemond, M. Levi, H. ten Cate, T. van der Poll, H.R. Buller, C.E. Hack, et al., Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades, *Clin. Sci.* 88 (5) (1995) 587–594.
- [36] P.W. Hermans, M.L. Hibberd, R. Booy, O. Daramola, J.A. Hazelzet, R. de Groot, et al., 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group, *Lancet* 354 (9178) (1999) 556–560.
- [37] R.G. Westendorp, J.J. Hottenga, P.E. Slagboom, Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock, *Lancet* 354 (9178) (1999) 561–563.
- [38] L.B. Hinshaw, P. Tekamp-Olson, A.C. Chang, P.A. Lee, F.B. Taylor Jr., C.K. Murray, et al., Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha), *Circ. Shock* 30 (3) (1990) 279–292.
- [39] E. Abraham, R. Wunderink, H. Silverman, T.M. Perl, S. Nasraway, H. Levy, et al., Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group, *JAMA* 273 (12) (1995) 934–941.
- [40] T. van der Poll, M. Levi, C.E. Hack, H. ten Cate, S.J. van Deventer, A.J. Eerenberg, et al., Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees, *J. Exp. Med.* 179 (4) (1994) 1253–1259.
- [41] J.M. Stouthard, M. Levi, C.E. Hack, C.H. Veenhof, H.A. Romijn, H.P. Sauerwein, et al., Interleukin-6 stimulates coagulation, not fibrinolysis, in humans, *Thromb. Haemost.* 76 (5) (1996) 738–742.
- [42] M.A. Boermeester, P. van Leeuwen, S.M. Coyle, G.J. Wolbink, C.E. Hack, Lowry, et al., Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis, *Arch. Surg.* 130 (7) (1995) 739–748.
- [43] S.R. Coughlin, Thrombin signalling and protease-activated receptors, *Nature* 407 (6801) (2000) 258–264.
- [44] N.C. Kaneider, E. Forster, B. Mosheimer, D.H. Sturm, C.J. Wiedermann, Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin, *Thromb. Haemost.* 90 (6) (2003) 1150–1157.
- [45] C.T. Esmon, New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins, *J. Exp. Med.* 196 (5) (2002) 561–564.
- [46] M. Yuxsel, K. Okajima, M. Uchiba, S. Horiuchi, H. Okabe, Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes, *Thromb. Haemost.* 88 (2) (2002) 267–273.
- [47] K. Murakami, K. Okajima, M. Uchiba, M. Johno, T. Nakagaki, H. Okabe, et al., Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats, *Blood* 87 (2) (1996) 642–647.
- [48] F.B. Taylor Jr., D.J. Stearns-Kurosawa, S. Kurosawa, G. Ferrell, A.C. Chang, Z. Laszik, et al., The endothelial cell protein C receptor aids in host defense against *Escherichia coli* sepsis, *Blood* 95 (5) (2000) 1680–1686.
- [49] M. Levi, J. Dorffler-Melly, P.H. Reitsma, H.R. Buller, S. Florquin, T. van der Poll, et al., Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein C deficient mice, *Blood* 101 (2003) 4823–4827.
- [50] R.P. Baughman, E.E. Lower, H.C. Flessa, D.J. Tollerud, Thrombocytopenia in the intensive care unit, *Chest* 104 (4) (1993) 1243–1247.
- [51] M. Levi, E. de Jonge, J. Meijers, The diagnosis of disseminated intravascular coagulation, *Blood Rev.* 16 (4) (2002) 217–223.
- [52] M. Levi, C.H. Toh, J. Thachil, H.G. Watson, Guidelines for the diagnosis and management of disseminated intravascular coagulation, *Br. J. Haematol.* 145 (1) (2009) 24–33.
- [53] C.E. Dempfle, S.A. Pfitzner, M. Dollman, K. Huck, G. Stehle, D.L. Heene, Comparison of immunological and functional assays for measurement of soluble fibrin, *Thromb. Haemost.* 74 (2) (1995) 673–679.
- [54] J.T. Horan, C.W. Francis, Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation, *Semin. Thromb. Hemost.* 6 (2001) 657–666.
- [55] D. Prisco, R. Paniccia, F. Bonechi, I. Francalanci, R. Abbate, G.F. Gesini, Evaluation of new methods for the selective measurement of fibrin and fibrinogen degradation products, *Thromb. Res.* 56 (4) (1989) 547–551.
- [56] A.F. Shorr, R.F. Trotta, S.A. Alkins, G.S. Hanzel, L.F. Diehl, D-dimer assay predicts mortality in critically ill patients without disseminated intravascular coagulation or venous thromboembolic disease, *Intensive Care Med.* 25 (2) (1999) 207–210.
- [57] M. Levi, J.C. Meijers, DIC: which laboratory tests are most useful, *Blood Rev.* 25 (1) (2011) 33–37.
- [58] C.E. Dempfle, M. Borggreffe, Point of care coagulation tests in critically ill patients, *Semin. Thromb. Hemost.* 34 (5) (2008) 445–450.
- [59] M. Levi, B.J. Hunt, A critical appraisal of point-of-care coagulation testing in critically ill patients, *J. Thromb. Haemost.* (2015).
- [60] P.I. Johansson, J. Stensballe, N. Vindelov, A. Perner, K. Espersen, Hypocoagulability, as evaluated by thrombelastography, at admission to the ICU is associated with increased 30-day mortality, *Blood Coagul. Fibrinolysis* 21 (2) (2010) 168–174.
- [61] M.S. Park, W.Z. Martini, M.A. Dubick, J. Salinas, S. Butenas, B.S. Kheirabadi, et al., Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time, *J. Trauma* 67 (2) (2009) 266–275.
- [62] P.W. Collins, L.I. Macchiavello, S.J. Lewis, N.J. Macartney, A.G. Saayman, R. Luddington, et al., Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls, *Br. J. Haematol.* 135 (2) (2006) 220–227.
- [63] M.C. Muller, J.C. Meijers, M.B. Vroom, N.P. Juffermans, Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review, *Crit. Care* 18 (1) (2014) R30.
- [64] T. Brenner, K. Schmidt, M. Delang, A. Mehrabi, T. Bruckner, C. Lichtenstern, et al., Viscoclastic and aggregometric point-of-care testing in patients with septic shock - cross-links between inflammation and haemostasis, *Acta Anaesthesiol. Scand.* 56 (10) (2012) 1277–1290.
- [65] F. Daudel, U. Kessler, H. Folly, J.S. Lienert, J. Takala, S.M. Jakob, Thromboelastometry for the assessment of coagulation abnormalities in early and established adult sepsis: a prospective cohort study, *Crit. Care* 13 (2) (2009) R42.
- [66] F.B. Taylor Jr., C.H. Toh, W.K. Hoots, H. Wada, M. Levi, Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation, *Thromb. Haemost.* 86 (5) (2001) 1327–1330.

- [67] H.K. Kim, K.H. Hong, C.H. Toh, Application of the international normalized ratio in the scoring system for disseminated intravascular coagulation, *J. Thromb. Haemost.* 8 (5) (2010) 1116–1118.
- [68] K. Bakhtiari, J.C. Meijers, E. de Jonge, M. Levi, Prospective validation of the international society of thrombosis and haemostasis scoring system for disseminated intravascular coagulation, *Crit. Care Med.* 32 (2004) 2416–2421.
- [69] C.H. Toh, W.K. Hoots, The scoring system of the scientific and standardisation committee on disseminated intravascular coagulation of the international society on thrombosis and haemostasis: a five year overview, *J. Thromb. Haemost.* 5 (2007) 604–606.
- [70] J.F. Dhainaut, S.B. Yan, D.E. Joyce, V. Pettilla, B.R. Basson, J.T. Brandt, et al., Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation, *J. Thromb. Haemost.* 2 (2004) 1924–1933.
- [71] H. Wada, E.C. Gabazza, H. Asakura, K. Koike, K. Okamoto, I. Maruyama, et al., Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for Overt DIC, *Am. J. Hematol.* 74 (1) (2003) 17–22.
- [72] H. Wada, J. Thachil, N.M. Di, P. Mathew, S. Kurosawa, S. Gando, et al., Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines, *J. Thromb. Haemost.* 10 (2013).
- [73] M. Levi, Settling the score for disseminated intravascular coagulation, *Crit. Care Med.* 33 (10) (2005) 2417–2418.
- [74] M. Levi, Platelets in critical illness, *Semin. Thromb. Hemost.* 42 (3) (2016) 252–257.
- [75] H. du Toit, A.R. Coetzee, D.O. Chalton, Heparin treatment in thrombin-induced disseminated intravascular coagulation in the baboon, *Crit. Care Med.* 19 (9) (1991) 1195–1200.
- [76] D.I. Feinstein, Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy, *Blood* 60 (2) (1982) 284–287 ([Review] [34 refs]).
- [77] R. Zarychanski, A.M. Abou-Setta, S. Kanji, A.F. Turgeon, A. Kumar, D.S. Houston, et al., The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis, *Crit. Care Med.* 43 (3) (2015) 511–518.
- [78] M. Levi, The dual face of heparin in severe infection, *Blood* 123 (2014) 947–948.
- [79] K. Boonyawat, M. Crowther, Venous thromboembolism prophylaxis in critically ill patients, *Semin. Thromb. Hemost.* 41 (1) (2015) 68–74.
- [80] M. Levi, M. Levy, M.D. Williams, I. Douglas, A. Artigas, M. Antonelli, et al., Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated), *Am. J. Respir. Crit. Care Med.* 176 (5) (2007) 483–490.
- [81] J. Dorffler-Melly, E. de Jonge, A.C. Pont, J. Meijers, M.B. Vroom, H.R. Buller, et al., Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors, *Lancet* 359 (9309) (2002) 849–850.
- [82] J.H. Levy, R.M. Sniecinski, I.J. Welsby, M. Levi, Antithrombin: anti-inflammatory properties and clinical applications, *Thromb. Haemost.* 115 (4) (2016) 712–728.
- [83] B.L. Warren, A. Eid, P. Singer, S.S. Pillay, P. Carl, I. Novak, et al., Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial, *JAMA* 286 (15) (2001) 1869–1878.
- [84] J. Kienast, M. Juers, C.J. Wiedermann, J.N. Hoffmann, H. Ostermann, R. Strauss, et al., Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation, *J. Thromb. Haemost.* 4 (1) (2006) 90–97.
- [85] T. Tagami, H. Matsui, H. Horiguchi, K. Fushimi, H. Yasunaga, Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study, *J. Thromb. Haemost.* 12 (9) (2014) 1470–1479.
- [86] T. Iba, D. Saitoh, H. Wada, H. Asakura, Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey, *Crit. Care* 18 (5) (2014) 497.
- [87] M. Levi, Activated protein C in sepsis: a critical review, *Curr. Opin. Hematol.* 15 (5) (2008) 481–486.
- [88] V.M. Ranieri, B.T. Thompson, P.S. Barie, J.F. Dhainaut, I.S. Douglas, S. Finfer, et al., Drotrecogin alfa (activated) in adults with septic shock, *N. Engl. J. Med.* 366 (22) (2012) 2055–2064.
- [89] J. Thachil, C.H. Toh, M. Levi, H.G. Watson, The withdrawal of activated protein C from the use in patients with severe sepsis and DIC [amendment to the BCSH guideline on disseminated intravascular coagulation], *Br. J. Haematol.* 10–2141 (2012).
- [90] M. Levi, T. van der Poll, Thrombomodulin in sepsis, *Minerva Anesthesiol.* 79 (3) (2013) 294–298.
- [91] K. Tsuruta, Y. Yamada, M. Serada, Y. Tanigawara, Model-based analysis of covariate effects on population pharmacokinetics of thrombomodulin alfa in patients with disseminated intravascular coagulation and normal subjects, *J. Clin. Pharmacol.* 51 (9) (2011) 1276–1285.
- [92] H. Saito, I. Maruyama, S. Shimazaki, Y. Yamamoto, N. Aikawa, R. Ohno, et al., Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial, *J. Thromb. Haemost.* 5 (1) (2007) 31–41.
- [93] J.L. Vincent, M.K. Ramesh, D. Ernest, S.P. LaRosa, J. Pahl, N. Aikawa, et al., A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation, *Crit. Care Med.* 41 (9) (2013) 2069–2079.
- [94] K. Yamakawa, M. Aihara, H. Ogura, H. Yuhara, T. Hamasaki, T. Shimazu, Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis, *J. Thromb. Haemost.* 13 (4) (2015) 508–519.
- [95] M. Levi, Recombinant soluble thrombomodulin: coagulation takes another chance to reduce sepsis mortality, *J. Thromb. Haemost.* 13 (4) (2015) 505–507.
- [96] M. Levi, M. Schultz, T. van der Poll, Sepsis and thrombosis, *Semin. Thromb. Hemost.* 39 (5) (2013) 559–566.
- [97] K.C. Wildhagen, P. Garcia de Frutos, C.P. Reutelingsperger, R. Schrijver, C. Areste, A. Ortega-Gomez, et al., Non-anticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis, *Blood* 123 (7) (2014) 1098–1101.
- [98] E.J. Kerschen, J.A. Fernandez, B.C. Cooley, X.V. Yang, R. Sood, L.O. Mosnier, et al., Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C, *J. Exp. Med.* 204 (10) (2007) 2439–2448.
- [99] M. Schouten, W.J. Wiersinga, M. Levi, P.T. van Der, Inflammation, endothelium, and coagulation in sepsis, *J. Leukoc. Biol.* 83 (3) (2008) 536–545.
- [100] M. Nieuwdorp, M.C. Meuwese, H.L. Mooij, M.H. van Lieshout, A. Hayden, M. Levi, et al., Tumor necrosis factor- $\alpha$  inhibition protects against endotoxin-induced endothelial glycocalyx perturbation, *Atherosclerosis* 202 (1) (2009) 296–303.